Skip to main content
PMC home page
Heart logoLink to Heart
. 1998 Jan;79(1):86–92. doi: 10.1136/hrt.79.1.86

β Blockers in heart failure: a comparison of a vasodilating β blocker with metoprolol

J Sanderson 1, S Chan 1, C Yu 1, L Yeung 1, W Chan 1, K Raymond 1, K Chan 1, K Woo 1
PMCID: PMC1728575  PMID: 9505927

Abstract

Objective—To determine whether a third generation vasodilating β blocker (celiprolol) has long term clinical advantages over metoprolol in patients with chronic heart failure.
Design—A double blind placebo controlled randomised trial.
Setting—University teaching Hospital.
Patients—50 patients with stable chronic heart failure (NYHA class II-IV) due to idiopathic dilated, ischaemic, or hypertensive cardiomyopathy, with left ventricular ejection fraction < 0.45.
Interventions—Celiprolol 200 mg daily (n = 21), metoprolol 50 mg twice daily (n = 19), or placebo (n = 10) for three months with a four week dose titration period. After the double blind period, patients entered an open label study (with placebo group receiving β blockers) and were assessed after one year.
Main outcome measures—Clinical response, efficacy, and tolerance were assessed by the Minnesota heart failure symptom questionnaire, six minute walk test, Doppler echocardiography (systolic and diastolic function), radionuclide ventriculography, and atrial and brain natriuretic peptides measured at baseline and after three months. 
Results—In the metoprolol group at 12 weeks v baseline there was a 47% reduction in symptom score (p < 0.001), improvement of NYHA class (mean (SEM), 2.6 (0.12) to 1.9 (0.13), p = 0.001), exercise distance (1246 (54) to 1402 (52) feet, p < 0.001), and left ventricular ejection fraction (26.9(3.1)% to 31(3.0)%, p = 0.016), and a fall in heart rate (resting, 79 (3) to 62 (3) beats/min, p < 0.001). In the celiprolol group there was a 38% reduction in symptom score (p = 0.02), less improvement in exercise distance (1191 (55) to 1256 (61) feet, p = 0.05), and no significant changes in NYHA class, left ventricular ejection fraction, or heart rate. Mortality at one year was 11% in metoprolol and 19% in the celiprolol group, and symptomatic improvement was maintained in the survivors.
Conclusions—Both drugs were well tolerated but the vasodilator properties of celiprolol do not seem to provide any obvious additional benefit in the long term treatment of heart failure. 

 Keywords: β blockers;  heart failure;  metoprolol;  celiprolol

Full Text

The Full Text of this article is available as a PDF (151.9 KB).

Figure 1  .

Figure 1  

Open in a new tab

Reduction in symptom score after 12 weeks of placebo (P), metoprolol (M), or celiprolol (C) treatment. *p = 0.073 v placebo.

Figure 2  .

Figure 2  

Open in a new tab

Changes in left ventricular ejection fraction (LVEF) after 12 weeks of placebo (P), metoprolol (M), or celiprolol (C) treatment. *p = 0.0049, †p = 0.028 v placebo.

Figure 3  .

Figure 3  

Open in a new tab

24 hour heart rate (Holter) analysis at baseline and after 12 weeks of treatment with placebo (P), metoprolol (M), or celiprolol (C).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andersson B., Caidahl K., di Lenarda A., Warren S. E., Goss F., Waldenström A., Persson S., Wallentin I., Hjalmarson A., Waagstein F. Changes in early and late diastolic filling patterns induced by long-term adrenergic beta-blockade in patients with idiopathic dilated cardiomyopathy. Circulation. 1996 Aug 15;94(4):673–682. doi: 10.1161/01.cir.94.4.673. [DOI] [PubMed] [Google Scholar]
  2. Benedict C. R., Shelton B., Johnstone D. E., Francis G., Greenberg B., Konstam M., Probstfield J. L., Yusuf S. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators. Circulation. 1996 Aug 15;94(4):690–697. doi: 10.1161/01.cir.94.4.690. [DOI] [PubMed] [Google Scholar]
  3. Bhambi B., Eghbali M. Effect of norepinephrine on myocardial collagen gene expression and response of cardiac fibroblasts after norepinephrine treatment. Am J Pathol. 1991 Nov;139(5):1131–1142. [PMC free article] [PubMed] [Google Scholar]
  4. Bittner V., Weiner D. H., Yusuf S., Rogers W. J., McIntyre K. M., Bangdiwala S. I., Kronenberg M. W., Kostis J. B., Kohn R. M., Guillotte M. Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. SOLVD Investigators. JAMA. 1993 Oct 13;270(14):1702–1707. [PubMed] [Google Scholar]
  5. Cohen G. I., Pietrolungo J. F., Thomas J. D., Klein A. L. A practical guide to assessment of ventricular diastolic function using Doppler echocardiography. J Am Coll Cardiol. 1996 Jun;27(7):1753–1760. doi: 10.1016/0735-1097(96)00088-5. [DOI] [PubMed] [Google Scholar]
  6. Cohn J. N., Levine T. B., Olivari M. T., Garberg V., Lura D., Francis G. S., Simon A. B., Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984 Sep 27;311(13):819–823. doi: 10.1056/NEJM198409273111303. [DOI] [PubMed] [Google Scholar]
  7. Doughty R. N., MacMahon S., Sharpe N. Beta-blockers in heart failure: promising or proved? J Am Coll Cardiol. 1994 Mar 1;23(3):814–821. doi: 10.1016/0735-1097(94)90773-0. [DOI] [PubMed] [Google Scholar]
  8. Dunn C. J., Spencer C. M. Celiprolol. An evaluation of its pharmacological properties and clinical efficacy in the management of hypertension and angina pectoris. Drugs Aging. 1995 Nov;7(5):394–411. doi: 10.2165/00002512-199507050-00006. [DOI] [PubMed] [Google Scholar]
  9. Eichhorn E. J., Bedotto J. B., Malloy C. R., Hatfield B. A., Deitchman D., Brown M., Willard J. E., Grayburn P. A. Effect of beta-adrenergic blockade on myocardial function and energetics in congestive heart failure. Improvements in hemodynamic, contractile, and diastolic performance with bucindolol. Circulation. 1990 Aug;82(2):473–483. doi: 10.1161/01.cir.82.2.473. [DOI] [PubMed] [Google Scholar]
  10. Eichhorn E. J., Bristow M. R. Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. Circulation. 1996 Nov 1;94(9):2285–2296. doi: 10.1161/01.cir.94.9.2285. [DOI] [PubMed] [Google Scholar]
  11. Hall J. A., Ferro A., Dickerson J. E., Brown M. J. Beta adrenoreceptor subtype cross regulation in the human heart. Br Heart J. 1993 Apr;69(4):332–337. doi: 10.1136/hrt.69.4.332. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hall S. A., Cigarroa C. G., Marcoux L., Risser R. C., Grayburn P. A., Eichhorn E. J. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol. 1995 Apr;25(5):1154–1161. doi: 10.1016/0735-1097(94)00543-y. [DOI] [PubMed] [Google Scholar]
  13. Krum H., Sackner-Bernstein J. D., Goldsmith R. L., Kukin M. L., Schwartz B., Penn J., Medina N., Yushak M., Horn E., Katz S. D. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation. 1995 Sep 15;92(6):1499–1506. doi: 10.1161/01.cir.92.6.1499. [DOI] [PubMed] [Google Scholar]
  14. Leimbach W. N., Jr, Wallin B. G., Victor R. G., Aylward P. E., Sundlöf G., Mark A. L. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation. 1986 May;73(5):913–919. doi: 10.1161/01.cir.73.5.913. [DOI] [PubMed] [Google Scholar]
  15. Mancia G. Sympathetic activation in congestive heart failure. Eur Heart J. 1990 Apr;11 (Suppl A):3–11. doi: 10.1093/eurheartj/11.suppl_a.3. [DOI] [PubMed] [Google Scholar]
  16. Nishimura R. A., Tajik A. J. Quantitative hemodynamics by Doppler echocardiography: a noninvasive alternative to cardiac catheterization. Prog Cardiovasc Dis. 1994 Jan-Feb;36(4):309–342. doi: 10.1016/s0033-0620(05)80037-4. [DOI] [PubMed] [Google Scholar]
  17. Packer M., Bristow M. R., Cohn J. N., Colucci W. S., Fowler M. B., Gilbert E. M., Shusterman N. H. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996 May 23;334(21):1349–1355. doi: 10.1056/NEJM199605233342101. [DOI] [PubMed] [Google Scholar]
  18. Pfeffer M. A., Stevenson L. W. Beta-adrenergic blockers and survival in heart failure. N Engl J Med. 1996 May 23;334(21):1396–1397. doi: 10.1056/NEJM199605233342109. [DOI] [PubMed] [Google Scholar]
  19. Sanderson J. E., Chan W. W., Hung Y. T., Chan S. K., Shum I. O., Raymond K., Woo K. S. Effect of low dose beta blockers on atrial and ventricular (B type) natriuretic factor in heart failure: a double blind, randomised comparison of metoprolol and a third generation vasodilating beta blocker. Br Heart J. 1995 Nov;74(5):502–507. doi: 10.1136/hrt.74.5.502. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Thomas J. A., Marks B. H. Plasma norepinephrine in congestive heart failure. Am J Cardiol. 1978 Feb;41(2):233–243. doi: 10.1016/0002-9149(78)90162-5. [DOI] [PubMed] [Google Scholar]
  21. Van Vliet P. D., Burchell H. B., Titus J. L. Focal myocarditis associated with pheochromocytoma. N Engl J Med. 1966 May 19;274(20):1102–1108. doi: 10.1056/NEJM196605192742002. [DOI] [PubMed] [Google Scholar]
  22. Waagstein F., Bristow M. R., Swedberg K., Camerini F., Fowler M. B., Silver M. A., Gilbert E. M., Johnson M. R., Goss F. G., Hjalmarson A. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet. 1993 Dec 11;342(8885):1441–1446. doi: 10.1016/0140-6736(93)92930-r. [DOI] [PubMed] [Google Scholar]
  23. Waagstein F., Hjalmarson A., Varnauskas E., Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J. 1975 Oct;37(10):1022–1036. doi: 10.1136/hrt.37.10.1022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Yamakawa H., Takeuchi M., Takaoka H., Hata K., Mori M., Yokoyama M. Negative chronotropic effect of beta-blockade therapy reduces myocardial oxygen expenditure for nonmechanical work. Circulation. 1996 Aug 1;94(3):340–345. doi: 10.1161/01.cir.94.3.340. [DOI] [PubMed] [Google Scholar]
  25. Yamamoto K., Redfield M. M., Nishimura R. A. Analysis of left ventricular diastolic function. Heart. 1996 Jun;75(6 Suppl 2):27–35. doi: 10.1136/hrt.75.6_suppl_2.27. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Yu C. M., Sanderson J. E., Chan S., Yeung L., Hung Y. T., Woo K. S. Right ventricular diastolic dysfunction in heart failure. Circulation. 1996 Apr 15;93(8):1509–1514. doi: 10.1161/01.cir.93.8.1509. [DOI] [PubMed] [Google Scholar]
  27. Yu C. M., Sanderson J. E., Shum I. O., Chan S., Yeung L. Y., Hung Y. T., Cockram C. S., Woo K. S. Diastolic dysfunction and natriuretic peptides in systolic heart failure. Higher ANP and BNP levels are associated with the restrictive filling pattern. Eur Heart J. 1996 Nov;17(11):1694–1702. doi: 10.1093/oxfordjournals.eurheartj.a014753. [DOI] [PubMed] [Google Scholar]
  28. Yusuf S., Tsuyuki R. Using exercise endpoints in heart failure trials: design considerations. Eur Heart J. 1996 Jan;17(1):4–6. doi: 10.1093/oxfordjournals.eurheartj.a014690. [DOI] [PubMed] [Google Scholar]

Articles from Heart are provided here courtesy of BMJ Publishing Group

RESOURCES